Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase II study of E7070 in patients with metastatic melanoma

Autor: Smyth, J.F. ^*, Aamdal, S., Awada, A., Dittrich, C., Caponigro, F., Schöffski, P., Gore, M., Lesimple, T., Djurasinovic, N., Baron, B., Ravic, M., Fumoleau, P., Punt, C.J.A.

Publikováno v: In Annals of Oncology January 2005 16(1):158-161

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)

Autor: Punt, C.J.A. ^*, Fumoleau, P., van de Walle, B., Faber, M.N., Ravic, M., Campone, M.

Publikováno v: In Annals of Oncology September 2001 12(9):1289-1293

Influence of Lornoxicam a New Non-steroidal Anti-inflammatory Drug on Lithium Pharmacokinetics.

Autor: Ravic, M.¹, Salas-Herrera, I.¹, Johnston, A.¹, Turner, P.¹, Foley, K.², Rosenow, D.²

Publikováno v: Human Psychopharmacology: Clinical & Experimental. Jul/Aug93, Vol. 8 Issue 4, p289-292. 4p.

Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide)

Autor: van Kesteren, Charlotte, Mathôt, R A A, Raymond, E, Armand, J P, Fumoleau, P, Punt, C, Ravic, M, Wanders, J, Beijnen, J H, Schellens, J H M

Publikováno v: British journal of clinical pharmacology, 54(5), 463-471. Wiley-Blackwell
British Journal of Clinical Pharmacology, 54, 463-71
British Journal of Clinical Pharmacology, 54, 5, pp. 463-71

Item does not contain fulltext AIMS: E7070 is a novel, sulphonamide anticancer agent currently under clinical development for the treatment of solid tumours. The aim of this study was to develop and validate limited sampling strategies for the predic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::29c5b6cf8c78ba7bccdaae4dfbdd9be0
https://doi.org/10.1046/j.1365-2125.2002.01684.x